Parkinson's Trial NCT06529744
Blood tests predict dementia progression
- Trial ID
- NCT06529744
- Official Title
- Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling
- Goal
- Blood tests predict dementia progression
- Status
- RECRUITING
- Sponsor
- University Health Network, Toronto
- Study Type
- OBSERVATIONAL
- Enrollment
- 500 participants
- Conditions
- Dementia, Alzheimer Disease, Dementia With Lewy Bodies, Vascular Dementia, Frontotemporal Dementia, Mild Cognitive Impairment, Corticobasal Syndrome, Progressive Supranuclear Palsy, Parkinson Disease, Primary Progressive Aphasia
Summary For Families
The goal is to improve how confidently clinicians can predict the course of Parkinson's and other neurodegenerative diseases that cause cognitive decline, so patients and families get clearer forecasts about progression and care needs. The approach is observational, gathering peripheral biomarkers like blood tests and other non-brain samples plus detailed clinical and cognitive assessments, then using integrative computational models to combine those signals and produce more accurate, individualized prognoses; it does not change your medical treatment. Adults 30 to 95 with possible or probable mild cognitive impairment or early dementia, who can consent, complete most study procedures, and have a study partner who sees them weekly are being sought.
Locations
- Baycrest, North York, Ontario, Canada
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to improve how confidently clinicians can predict the course of Parkinson's and other neurodegenerative diseases that cause cognitive decline, so patients and families get clearer forecasts about progression and care needs. The approach is observational, gathering peripheral biomarkers like blood tests and other non-brain samples plus detailed clinical and cognitive assessments, then using integrative computational models to combine those signals and produce more accurate, individualized prognoses; it does not change your medical treatment. Adults 30 to 95 with possible or probable mild cognitive impairment or early dementia, who can consent, complete most study procedures, and have a study partner who sees them weekly are being sought.
- Who can participate?
- Participants must be between 30 Years and 95 Years.
- Where is this trial located?
- This trial is recruiting at 4 locations.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 3 years.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- This is an observational study, so there is no placebo and no experimental treatment is assigned. Researchers observe and collect information while you continue your usual care.
- What procedures are involved in this trial?
- Based on the protocol, this trial involves: Lumbar puncture (spinal tap) (invasive); Biopsy (invasive); Skin biopsy (minimally invasive); MRI scan (non-invasive); Questionnaires & surveys (non-invasive). Confirm the full schedule with the study coordinator.